PVT1 and posterior cortical atrophy: The promise of these potential biomarkers to improve the clinical diagnosis of PCa, among this most vulnerable population group, was subsequently elevated by the development of a non-invasive copy number-based quantification assay for detecting PVT1-derived transcripts from prostate tissues, serum, and urine samples (17).